Mutational patterns and correlated amino acid substitutions in the HIV‐1 protease after virological failure to nelfinavir‐ and lopinavir/ritonavir‐based treatments
- 13 September 2007
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 79 (11) , 1617-1628
- https://doi.org/10.1002/jmv.20986
Abstract
Human immunodeficiency virus type 1 (HIV‐1) antiviral drug resistance is a major consequence of therapy failure and compromises future therapeutic options. Nelfinavir and lopinavir/ritonavir‐based therapies have been widely used in the treatment of HIV‐infected patients, in combination with reverse transcriptase inhibitors. The aim of this observational study was the identification and characterization of mutations or combinations of mutations associated with resistance to nelfinavir and lopinavir/ritonavir in treated patients. Nucleotide sequences of 1,515 subtype B HIV‐1 isolates from 1,313 persons with different treatment histories (including naïve and treated patients) were collected in 31 Spanish hospitals over the years 2002–2005. Chi‐square contingency tests were performed to detect mutations associated with failure to protease inhibitor‐based therapies, and correlated mutations were identified using statistical methods. Virological failure to nelfinavir was associated with two different mutational pathways. D30N and N88D appeared mostly in patients without previous exposure to protease inhibitors, while K20T was identified as a secondary resistance mutation in those patients. On the other hand, L90M together with L10I, I54V, A71V, G73S, and V82A were selected in protease inhibitor‐experienced patients. A series of correlated mutations including L10I, M46I, I54V, A71V, G73S, and L90M appeared as a common cluster of amino acid substitutions, associated with failure to lopinavir/ritonavir‐based treatments. Despite the relatively high genetic barrier of some protease inhibitors, a relatively small cluster of mutations, previously selected under drug pressure, can seriously compromise the efficiency of nelfinavir‐ and lopinavir/ritonavir‐based therapies. J. Med. Virol. 79:1617–1628, 2007.Keywords
This publication has 57 references indexed in Scilit:
- Bayesian network analysis of resistance pathways against HIV-1 protease inhibitorsInfection, Genetics and Evolution, 2007
- N88D Facilitates the Co-occurrence of D30N and L90M and the Development of Multidrug Resistance in HIV Type 1 Protease following Nelfinavir Treatment FailureAIDS Research and Human Retroviruses, 2006
- HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimensJournal of Clinical Laboratory Analysis, 2005
- Minor Mutations in HIV Protease at Baseline and Appearance of Primary Mutation 90M in Patients for Whom Their First Protease‐Inhibitor Antiretroviral Regimens FailedThe Journal of Infectious Diseases, 2004
- R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing RegimenAntimicrobial Agents and Chemotherapy, 2003
- Treatment with Indinavir, Efavirenz, and Adefovir after Failure of Nelfinavir TherapyThe Journal of Infectious Diseases, 2003
- Lopinavir/RitonavirDrugs, 2003
- Phenotypic Cross-Resistance to Nelfinavir: The Role of Prior Antiretroviral Therapy and the Number of Mutations in the Protease GeneAIDS Research and Human Retroviruses, 2001
- Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pHProtein Science, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998